Shao-Fei Liu, Mariya M Kucherenko, Pengchao Sang, Qiuhua Li, Juquan Yao, Netra Nambiar Veetil, Tara Gransar, Ioana Alesutan, Jakob Voelkl, Gabriela Salinas, Jana Grune, Szandor Simmons, Christoph Knosalla, Wolfgang M Kuebler
{"title":"RUNX2 由 TAZ 稳定,并在左心疾病导致的肺动脉高压中驱动肺动脉钙化和肺血管重塑。","authors":"Shao-Fei Liu, Mariya M Kucherenko, Pengchao Sang, Qiuhua Li, Juquan Yao, Netra Nambiar Veetil, Tara Gransar, Ioana Alesutan, Jakob Voelkl, Gabriela Salinas, Jana Grune, Szandor Simmons, Christoph Knosalla, Wolfgang M Kuebler","doi":"10.1183/13993003.00844-2023","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Calcification is common in chronic vascular disease, yet its role in pulmonary hypertension due to left heart disease is unknown. Here, we probed for the role of runt-related transcription factor-2 (RUNX2), a master transcription factor in osteogenesis, and its regulation by the HIPPO pathway transcriptional coactivator with PDZ-binding motif (TAZ) in the osteogenic reprogramming of pulmonary artery smooth muscle cells and vascular calcification in patients with pulmonary hypertension due to left heart disease. We similarly examined its role using an established rat model of pulmonary hypertension due to left heart disease induced by supracoronary aortic banding.</p><p><strong>Methods: </strong>Pulmonary artery samples were collected from patients and rats with pulmonary hypertension due to left heart disease. Genome-wide RNA sequencing was performed, and pulmonary artery calcification assessed. Osteogenic signalling <i>via</i> TAZ and RUNX2 was delineated by protein biochemistry. <i>In vivo</i>, the therapeutic potential of RUNX2 or TAZ inhibition by CADD522 or verteporfin was tested in the rat model.</p><p><strong>Results: </strong>Gene ontology term analysis identified significant enrichment in ossification and osteoblast differentiation genes, including <i>RUNX2</i>, in pulmonary arteries of patients and lungs of rats with pulmonary hypertension due to left heart disease. Pulmonary artery calcification was evident in both patients and rats. Both TAZ and RUNX2 were upregulated and activated in pulmonary artery smooth muscle cells of patients and rats. Co-immunoprecipitation revealed a direct interaction of RUNX2 with TAZ in pulmonary artery smooth muscle cells. TAZ inhibition or knockdown decreased RUNX2 abundance due to accelerated RUNX2 protein degradation rather than reduced <i>de novo</i> synthesis. Inhibition of either TAZ or RUNX2 attenuated pulmonary artery calcification, distal lung vascular remodelling and pulmonary hypertension development in the rat model.</p><p><strong>Conclusion: </strong>Pulmonary hypertension due to left heart disease is associated with pulmonary artery calcification that is driven by TAZ-dependent stabilisation of RUNX2, causing osteogenic reprogramming of pulmonary artery smooth muscle cells. The TAZ-RUNX2 axis may present a therapeutic target in pulmonary hypertension due to left heart disease.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"64 5","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease.\",\"authors\":\"Shao-Fei Liu, Mariya M Kucherenko, Pengchao Sang, Qiuhua Li, Juquan Yao, Netra Nambiar Veetil, Tara Gransar, Ioana Alesutan, Jakob Voelkl, Gabriela Salinas, Jana Grune, Szandor Simmons, Christoph Knosalla, Wolfgang M Kuebler\",\"doi\":\"10.1183/13993003.00844-2023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Calcification is common in chronic vascular disease, yet its role in pulmonary hypertension due to left heart disease is unknown. Here, we probed for the role of runt-related transcription factor-2 (RUNX2), a master transcription factor in osteogenesis, and its regulation by the HIPPO pathway transcriptional coactivator with PDZ-binding motif (TAZ) in the osteogenic reprogramming of pulmonary artery smooth muscle cells and vascular calcification in patients with pulmonary hypertension due to left heart disease. We similarly examined its role using an established rat model of pulmonary hypertension due to left heart disease induced by supracoronary aortic banding.</p><p><strong>Methods: </strong>Pulmonary artery samples were collected from patients and rats with pulmonary hypertension due to left heart disease. Genome-wide RNA sequencing was performed, and pulmonary artery calcification assessed. Osteogenic signalling <i>via</i> TAZ and RUNX2 was delineated by protein biochemistry. <i>In vivo</i>, the therapeutic potential of RUNX2 or TAZ inhibition by CADD522 or verteporfin was tested in the rat model.</p><p><strong>Results: </strong>Gene ontology term analysis identified significant enrichment in ossification and osteoblast differentiation genes, including <i>RUNX2</i>, in pulmonary arteries of patients and lungs of rats with pulmonary hypertension due to left heart disease. Pulmonary artery calcification was evident in both patients and rats. Both TAZ and RUNX2 were upregulated and activated in pulmonary artery smooth muscle cells of patients and rats. Co-immunoprecipitation revealed a direct interaction of RUNX2 with TAZ in pulmonary artery smooth muscle cells. TAZ inhibition or knockdown decreased RUNX2 abundance due to accelerated RUNX2 protein degradation rather than reduced <i>de novo</i> synthesis. Inhibition of either TAZ or RUNX2 attenuated pulmonary artery calcification, distal lung vascular remodelling and pulmonary hypertension development in the rat model.</p><p><strong>Conclusion: </strong>Pulmonary hypertension due to left heart disease is associated with pulmonary artery calcification that is driven by TAZ-dependent stabilisation of RUNX2, causing osteogenic reprogramming of pulmonary artery smooth muscle cells. The TAZ-RUNX2 axis may present a therapeutic target in pulmonary hypertension due to left heart disease.</p>\",\"PeriodicalId\":12265,\"journal\":{\"name\":\"European Respiratory Journal\",\"volume\":\"64 5\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Respiratory Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.00844-2023\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1183/13993003.00844-2023","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"Print","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
背景:钙化在慢性血管疾病中很常见,但它在左心疾病引起的肺动脉高压中的作用尚不清楚。在此,我们探究了成骨过程中的主转录因子 RUNT 相关转录因子-2(RUNX2)及其受 HIPPO 通路转录辅激活因子 PDZ 结合基调(TAZ)调控在左心肺动脉高压患者肺动脉平滑肌细胞成骨重塑和血管钙化过程中的作用。同样,我们还利用已建立的大鼠模型研究了TAZ在冠状动脉上束带诱发的左心肺动脉高压中的作用:方法:从左心病肺动脉高压患者和大鼠身上采集肺动脉样本。方法:从左心病肺动脉高压患者和大鼠身上采集肺动脉样本,进行全基因组 RNA 测序,并评估肺动脉钙化情况。通过蛋白质生物化学方法确定了TAZ和RUNX2的成骨信号。在大鼠模型中测试了CADD522或verteporfin抑制RUNX2或TAZ的体内治疗潜力:结果:基因本体术语分析发现,在左心疾病导致的肺动脉高压患者和大鼠肺中,包括RUNX2在内的骨化和成骨细胞分化基因明显富集。患者和大鼠的肺动脉钙化都很明显。在患者和大鼠的肺动脉平滑肌细胞中,TAZ和RUNX2都被上调和激活。共免疫沉淀显示,肺动脉平滑肌细胞中的RUNX2与TAZ存在直接相互作用。抑制或敲除TAZ会降低RUNX2的丰度,这是由于RUNX2蛋白降解加速而非从头合成减少所致。在大鼠模型中,抑制TAZ或RUNX2可减轻肺动脉钙化、远端肺血管重塑和肺动脉高压的发展:结论:左心病导致的肺动脉高压与肺动脉钙化有关,而肺动脉钙化是由依赖于TAZ的RUNX2稳定所驱动的,它导致了肺动脉平滑肌细胞的成骨性重编程。TAZ-RUNX2轴可能是左心疾病所致肺动脉高压的治疗靶点。
RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease.
Background: Calcification is common in chronic vascular disease, yet its role in pulmonary hypertension due to left heart disease is unknown. Here, we probed for the role of runt-related transcription factor-2 (RUNX2), a master transcription factor in osteogenesis, and its regulation by the HIPPO pathway transcriptional coactivator with PDZ-binding motif (TAZ) in the osteogenic reprogramming of pulmonary artery smooth muscle cells and vascular calcification in patients with pulmonary hypertension due to left heart disease. We similarly examined its role using an established rat model of pulmonary hypertension due to left heart disease induced by supracoronary aortic banding.
Methods: Pulmonary artery samples were collected from patients and rats with pulmonary hypertension due to left heart disease. Genome-wide RNA sequencing was performed, and pulmonary artery calcification assessed. Osteogenic signalling via TAZ and RUNX2 was delineated by protein biochemistry. In vivo, the therapeutic potential of RUNX2 or TAZ inhibition by CADD522 or verteporfin was tested in the rat model.
Results: Gene ontology term analysis identified significant enrichment in ossification and osteoblast differentiation genes, including RUNX2, in pulmonary arteries of patients and lungs of rats with pulmonary hypertension due to left heart disease. Pulmonary artery calcification was evident in both patients and rats. Both TAZ and RUNX2 were upregulated and activated in pulmonary artery smooth muscle cells of patients and rats. Co-immunoprecipitation revealed a direct interaction of RUNX2 with TAZ in pulmonary artery smooth muscle cells. TAZ inhibition or knockdown decreased RUNX2 abundance due to accelerated RUNX2 protein degradation rather than reduced de novo synthesis. Inhibition of either TAZ or RUNX2 attenuated pulmonary artery calcification, distal lung vascular remodelling and pulmonary hypertension development in the rat model.
Conclusion: Pulmonary hypertension due to left heart disease is associated with pulmonary artery calcification that is driven by TAZ-dependent stabilisation of RUNX2, causing osteogenic reprogramming of pulmonary artery smooth muscle cells. The TAZ-RUNX2 axis may present a therapeutic target in pulmonary hypertension due to left heart disease.
期刊介绍:
The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.